Glenmark Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 31 Jan 2026
Result Summary
- Glenmark Pharmaceuticals Ltd reported a 36.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 15.4%.
- Its expenses for the quarter were down by 17.2% QoQ and up 8.9% YoY.
- The net profit decreased 33.9% QoQ and increased 15.9% YoY.
- The earnings per share (EPS) of Glenmark Pharmaceuticals Ltd stood at 14.28 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 3945.08 | 6247.50 | 3418.68 | -36.9% | 15.4% |
Total Expenses | 3226.75 | 3894.98 | 2962.35 | -17.2% | 8.9% |
Profit Before Tax | 534.00 | 967.40 | 456.33 | -44.8% | 17.0% |
Tax | 130.77 | 356.97 | 108.30 | -63.4% | 20.7% |
Profit After Tax | 403.23 | 610.43 | 348.03 | -33.9% | 15.9% |
Earnings Per Share | 14.28 | 21.62 | 12.33 | -34.0% | 15.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Glenmark Pharmaceuticals Ltd is a global pharmaceutical company known for its presence in the research, development, manufacturing, and marketing of branded and generic formulations. The company operates across multiple therapeutic areas including dermatology, respiratory, and oncology. It is also engaged in the development of new chemical entities and biosimilars. As a key player in the pharmaceutical industry, Glenmark is involved in both domestic and international markets. Recent major developments for Glenmark include strategic partnerships and product launches, contributing to its growth and market expansion. Specific recent developments or strategic initiatives are not available from the provided data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Glenmark Pharmaceuticals Ltd reported a total income of ₹3945.08 crores. This represents a year-over-year (YoY) increase of 15.4% compared to ₹3418.68 crores in Q3FY25. However, there was a quarter-over-quarter (QoQ) decline of 36.9% from ₹6247.50 crores in Q2FY26. The significant YoY growth may reflect the company's expanding operations or successful product lines, while the QoQ decline might be indicative of seasonal fluctuations or other temporal factors affecting income.
Profitability
For Q3FY26, Glenmark Pharmaceuticals Ltd achieved a profit before tax of ₹534.00 crores, marking a YoY increase of 17.0% from ₹456.33 crores in Q3FY25. The profit after tax for the same period stood at ₹403.23 crores, which is a 15.9% increase YoY from ₹348.03 crores. Despite these positive annual trends, the company experienced a QoQ decrease in profit before tax of 44.8% from ₹967.40 crores and a decrease in profit after tax of 33.9% from ₹610.43 crores in Q2FY26. The tax expense in Q3FY26 was ₹130.77 crores, which is a 20.7% increase YoY but a substantial reduction of 63.4% QoQ from ₹356.97 crores. These figures indicate a complex profitability landscape within the quarter.
Operating Metrics
The earnings per share (EPS) for Glenmark Pharmaceuticals Ltd in Q3FY26 was ₹14.28, reflecting a YoY increase of 15.8% from ₹12.33 in Q3FY25. However, there was a QoQ decline of 34.0% from ₹21.62 in Q2FY26. Total expenses for Q3FY26 were ₹3226.75 crores, witnessing an 8.9% increase YoY from ₹2962.35 crores, but a 17.2% decrease QoQ from ₹3894.98 crores. The changes in these metrics suggest variations in operational efficiency and cost management strategies over different time periods. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio are not explicitly provided in the data, limiting the analysis to direct financial figures shared.